Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial
Authors' conclusion
Dapagliflozin showed improvements in diastolic function, atrial function and exercise capacity in in patients with T2DM and SBHF, but no change in GLS.
Study context
- Population
- People with well-controlled T2DM and LV dysfunction (stage B HF); screened cohort age 73 ± 7 years, 159 women139 with LVD randomized
- Participants
- 262 people
- Comparison
- Dapagliflozin 10 mg/day vs placebo
- Primary endpoint
- Global longitudinal strain (GLS)
- Follow-up
- Baseline to 6 months
Methodological detailsrandomized 1:1, placebo-controlled
- Randomized 1:1
- Placebo-controlled
Primary result
As reported in the abstract
ΔGLS
- No difference in ΔGLS from baseline to 6 months between dapagliflozin and placebo
- Between Dapagliflozin and Placebo: P = 0.18
Further findings
Abnormal GLS (< 16%) · 6 months · less common with dapagliflozin
P = 0.03
| Outcome | Dapagliflozin | Placebo | P value |
|---|---|---|---|
| Change in LA volume index · baseline to 6 monthsReduction with dapagliflozin | - 2.0 ± 9.0 | 0.03 ± 8.6 | P = 0.002 |
| Change in average E/e′ · baseline to 6 monthsReduction with dapagliflozin | - 0.1 ± 2.4 | 0.7 ± 2.4 | P < 0.001 |
| Change in LA reservoir strain · baseline to 6 monthsImproved with dapagliflozin | 1.8 ± 4.0 | - 0.2 ± 4.0 | P = 0.02 |
| Δ6MWD · 6 monthsImproved with dapagliflozin | 17 ± 46 m | 2 ± 73 m | P = 0.001 |
Changes between 6 and 24 months
- No significant differences between 6 and 24 months
Original publication
Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial. Cardiovasc Diabetol. Published 30 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →